Complementary multi‐omics profiling of chronic thromboembolic pulmonary hypertension reveals immune cell alterations, epigenetic changes, and genetically supported candidate genes
Animal Models and Experimental Medicine · 2026-04 · 9 (4) · 641-651
DOI: 10.1002/ame2.70166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, online erschienen am 31.03.2026. Verfasst von Xiaopeng Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Hypertension, Pulmonary, Multiomics, Pulmonary Embolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, China, National High Level Hospital Clinical Research Funding-Elite Medical Professionals Project of China-Japan Friendship Hospital, China.
Abstract (Originalsprache)
Background
Chronic thromboembolic pulmonary hypertension (CTEPH) is driven by unresolved pulmonary arterial thrombi and involves complex processes such as vascular remodeling and immune dysregulation. Early identification of molecular markers may support more accurate diagnosis and individualized therapy.
Methods
We integrated anthropometric and biochemical data with single‐cell RNA sequencing (scRNA‐seq), DNA methylation, and Mendelian randomization (MR) analyses. scRNA‐seq data were analyzed to determine altered cell populations and pathways. MR and colocalization analyses were conducted to identify genetically supported candidates related to CTEPH. Results scRNA‐seq analysis revealed altered immune composition, with a modest increase in NK cells and an angiogenesis‐associated enrichment of monocytes and HSC‐G‐CSF cells in CTEPH patients, accompanied by activation of toll‐like receptor and MAPK signaling pathways. MR and colocalization identified several genetically associated genes—CLEC7A, TNFSF13B, LRP1, ETS1, and FGR—of which ETS1 and FGR demonstrated good diagnostic performance. DNA methylation analysis indicated marked alterations in chromatin assembly and epigenetic regulation.
Conclusions
This multi‐omics study highlights critical genes, epigenetic features, and immune‐related cell populations associated with CTEPH. These findings improve understanding of disease mechanisms and offer potential biomarkers for early diagnosis and personalized management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing, China.
- Department of Anesthesiology, China-Japan Friendship Hospital, Beijing, China.
ORCID-Profile: Yanan Zhen
Förderung
- National High Level Hospital Clinical Research Funding, China
- National High Level Hospital Clinical Research Funding-Elite Medical Professionals Project of China-Japan Friendship Hospital, China
Zitieren
APA
Liu, X., Zheng, X., Zhang, Y., Fang, Y., & Zhen, Y. (2026). Complementary multi‐omics profiling of chronic thromboembolic pulmonary hypertension reveals immune cell alterations, epigenetic changes, and genetically supported candidate genes. Animal Models and Experimental Medicine, 9(4), 641-651. https://doi.org/10.1002/ame2.70166
Vancouver
Liu X, Zheng X, Zhang Y, Fang Y, Zhen Y. Complementary multi‐omics profiling of chronic thromboembolic pulmonary hypertension reveals immune cell alterations, epigenetic changes, and genetically supported candidate genes. Animal Models and Experimental Medicine. 2026;9(4):641-651. doi:10.1002/ame2.70166
BibTeX
@article{Liu2026,
author = {Liu, Xiaopeng and Zheng, Xia and Zhang, Yajun and Fang, Yinghui and Zhen, Yanan},
title = {Complementary multi‐omics profiling of chronic thromboembolic pulmonary hypertension reveals immune cell alterations, epigenetic changes, and genetically supported candidate genes},
journal = {Animal Models and Experimental Medicine},
year = {2026},
volume = {9},
number = {4},
pages = {641--651},
doi = {10.1002/ame2.70166}
}
EUVIMED